Drugs Made In America Acquisition (NASDAQ:DMAA) Trading Up 0.1% – Time to Buy?

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) rose 0.1% during trading on Tuesday . The stock traded as high as $10.84 and last traded at $10.84. 1,551 shares were traded during mid-day trading, a decline of 97% from the average session volume of 48,260 shares. The stock had previously closed at $10.83.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition Price Performance

The firm has a 50-day moving average price of $10.73 and a 200-day moving average price of $10.62.

Drugs Made In America Acquisition (NASDAQ:DMAA) last issued its quarterly earnings results on Friday, August 14th. The company reported $0.06 earnings per share for the quarter.

Institutional Trading of Drugs Made In America Acquisition

A number of hedge funds and other institutional investors have recently modified their holdings of DMAA. Radcliffe Capital Management L.P. lifted its position in Drugs Made In America Acquisition by 3.5% during the 4th quarter. Radcliffe Capital Management L.P. now owns 546,808 shares of the company’s stock valued at $5,673,000 after acquiring an additional 18,708 shares during the period. Lineage Point Capital LP bought a new position in shares of Drugs Made In America Acquisition during the fourth quarter valued at approximately $330,000. Clear Street Group Inc. lifted its holdings in shares of Drugs Made In America Acquisition by 55.5% during the fourth quarter. Clear Street Group Inc. now owns 325,973 shares of the company’s stock valued at $3,382,000 after purchasing an additional 116,407 shares during the last quarter. Sona Asset Management US LLC purchased a new position in shares of Drugs Made In America Acquisition during the first quarter valued at approximately $1,706,000. Finally, L1 Global Manager Pty Ltd bought a new stake in shares of Drugs Made In America Acquisition in the 4th quarter worth approximately $2,075,000.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is a special purpose acquisition company, or SPAC. The company was formed to identify and complete a merger, acquisition, or similar business combination with an operating company.

Its stated focus is on businesses in the pharmaceutical, healthcare, and related life sciences sectors, particularly companies involved in the development, manufacturing, or distribution of products in the United States. Unlike an operating pharmaceutical company, Drugs Made In America Acquisition Corp.